Colon Cancer: State of the Art
|
|
- Hugh Jennings
- 5 years ago
- Views:
Transcription
1 Colon Cancer: State of the Art Heinz-Josef Lenz Professor of Medicine and Preventive Medicine Associate Director, Clinical Research J Terrence Lanni Chair in Cancer Research Co-Director, USC Center for Molecular Pathways and Drug Discovery USC/Norris Comprehensive Cancer Center Los Angeles, California
2 HEINZ-JOSEF LENZ COLORECTAL CANCER: STATE OF THE ART ADVISORY BOARDS: BAYER, BOEHRINGER-INGELHEIM, MERCKSERONO, ROCHE, GENENTECH, BMS CLINICAL TRIAL SUPPORT: ROCHE, BAYER, TAIHO, DAICHI, INCYTE, BOEHRINGER-INGELHEIM, BMS, PFIZER, MERCK, MERCKSERONO, SWOG, NCI, NIH THE SPEAKER WILL DIRECTLY DISCLOSURE THE USE OF PRODUCTS FOR WHICH ARE NOT LABELED (E.G., OFF LABEL USE) OR IF THE PRODUCT IS STILL INVESTIGATIONAL. 14th Annual California Cancer Conference Consortium August 10-12, 2018
3
4 The Colorectal Cancer Subtyping Consortium (CRCSC) identifies a network of molecular subtypes Subtype 2.2 TA C5 D Subtype 1.3 B C1 C4 Subtype 1.1 CCS3 E Stem-like B_score CCS1 Group A Group B C_score Enterocyte CMS2 Group C CMS4 Group D C2 C Inflammatory CCS2 A_score Subtype 2.1 C3 Goblet-like Group E Group F Subtype 1.2 CMS1 A CMS3 Dienstmann R, et al. ASCO 2014 (Abstract No. 3511)
5 Proportion Without Event OS All Patients by CMS Subtype CMS Events/Total Median (95% CI) CMS1 85/ ( ) CMS2 173/ ( ) CMS3 58/ ( ) CMS4 127/ ( ) Logrank P-value: < Months From Randomization Presented by: Heinz Josef Lenz
6 Proportion Without Event OS CMS1 Patients by Arm Arm Events/Total Median (95% CI) Bevacizumab 36/ ( ) Cetuximab 49/ ( ) Logrank P-value: Months From Randomization Presented by: Heinz Josef Lenz
7 Proportion Without Event OS CMS2 Patients by Arm Arm Events/Total Median (95% CI) Bevacizumab 94/ ( ) Cetuximab 79/ ( ) Logrank P-value: Months From Randomization Presented by: Heinz Josef Lenz
8 Heterogeneity also exists within individual tumors Ding et al., Nature 2010 Mutations present in 5 90% of sequencing reads from one tumor Navin et al., Nature 2011 Independent subclones coexisting in a single anatomic site in breast Gerlinger et al., NEJM 2012 Two-thirds of mutations in single biopsies were not uniformly detectable throughout all sampled regions Both sensitive and resistant RNA expression patterns
9 Intra-tumor copy number heterogeneity in CRC at the single gland level C. Curtis & colleagues
10 Liquid Biopsies Tumor specific change (e.g. Mutation) Tumor Tumor cell release DNA and RNA Circulating Tumor Cells (CTC) CTC Circulating tumor DNA Normal DNA Blood Vessel Circulating tumor RNA
11 MGH GI Cancer Center Liquid Biopsy Program HER2 amp CRC (n=2) MET amp 5% gastric (n=2) 5% FGFR2 gastric (n=1) 2% FGFR2 biliary (n=8) 21% BRAF mcrc (n=5) 13% RAS WT CRC (n=21) 54% single mechanism identifed (n=17) 43% no mechanism identified (n=8) 21% multiple mechansims identified (n=14) 36% N=39 Routine liquid biopsy assessment can effectively identify mechanisms of resistance across different tumor types and treatments Mechanism of resistance identified in 80% 36% with multiple resistance mechanisms (range 2-12; median 3) In patients with matched tumor biopsies, ctdna identified additional resistance mechanisms in 64%
12 EGFR antibodies in RAS-WT CRC Anti-EGFR antibodies RTK EGFR 10 distinct resistance alterations identified across 21 patients KRAS mutations RAS KRAS NRAS HRAS KRAS amplification EGFR ECD mutations MET amplification CRAF ARAF BRAF ERBB2 amplification Novel MEK1 mutation MEK Some patients with 5 or more alterations present in ctdna ERK PROLIFERATION AND SURVIVAL
13 Therapeutic intervention in preclinical trials to overcomeresistance to anti-egfr antibody blockade. A Bertotti et al. Nature 000, 1-5 (2015) doi: /nature14969
14 Interesting Findings 1. In a small series of 10 patients who all had mt ras in tissue and liquid biopsy treated with bev based chemotherapy. 5/10 changed to wt Ras under chemotherapy ) Gazzaniga et al Annals of Oncology (2017) 28 (suppl_5): v573-v594) 2. Case report in JCO Precision Oncology from same group reported PR in one of this patient treated with cetuximab 14
15 ESMO, 2016 ASCO, ESMO, JUNE, SEP, ST LINE MET / ADVANCED COLORECTAL KRAS wt All RAS wt Codons 12 & 13 CALGB/SWOG FOLFIRI or FOLFOX MD choice N N = = * N = 526 Chemo + Cetuximab Chemo Cetuximab OS = mos mos PFS PFS = = mos OS = 32.5 mos : NO DIFFERENCE Chemo + Bevacizumab Chemo OS + = Bevacizumab OS = mos PFS PFS = = mos OS = 31.2 mos * Right or left-sided primary Included in sidedness analysis
16 80405: Overall Survival by Sidedness (all RAS wt) Side N (Events) Median (95% CI) HR (95% CI) p Left Right 325 (238) 149 (114) 35.2 ( ) ( ) ( ) 0.009
17 80405: OS by Sidedness (Bevacizumab) Side N (Events) Median (95% CI) HR (95% CI) Adjusted p Left Right 152 (119) 78 (58) 32.6 ( ) ( ) ( ).50
18 80405: OS by Sidedness (Cetuximab) Side N (Events) Median (95% CI) HR (95% CI) Adjuste d P Left Right 173 (119) 71 (56) 39.3 ( ) ( ) ( ) 0.001
19 80405: Sidedness Predictive for Biologics Biologic by 1 Side Interaction BIOLOGIC SIDE OF PRIMARY HAZARD RATIO 95% CI P (adjusted*) Any biologic OS Cetux v Bev; left Cetux v Bev; right 1.81 (1.15, 2.84) P int = PFS 1.94 (1.28, 2.95) P int = Cetux v Bev OS Left 0.77 (0.59, 0.99) 0.04 PFS 0.84 (0.66, 1.06) 0.15 Cetux v Bev OS Right 1.36 (0.93, 1.99) 0.10 PFS 1.64 (1.15, 2.36) *Adjusted for biologic, protocol chemotherapy, prior adjuvant therapy, prior RT, age, sex, synchronous disease, in place primary, liver metastases
20 Probability of PFS Probability of OS FIRE-3: Right-sided tumors Progression-free survival Overall survival 1.0 Right-sided mcrc Cetuximab + FOLFIRI (n=38) Bevacizumab + FOLFIRI (n=50) 1.0 Right-sided mcrc Cetuximab + FOLFIRI (n=38) Bevacizumab + FOLFIRI (n=50) HR = 1.44 (95% CI: ) p = HR = 1.31 (95% CI: ) p = Cetuximab + FOLFIRI Bevacizumab + FOLFIRI Months Numbers at Risk Cetuximab + FOLFIRI Bevacizumab + FOLFIRI Months Numbers at Risk
21 Probability of PFS Probability of OS FIRE-3: Left-sided tumors Progression-free survival Overall survival A 1.0 Left-sided mcrc Cetuximab + FOLFIRI (n=157) Bevacizumab + FOLFIRI (n=149) B 1.0 Left-sided mcrc Cetuximab + FOLFIRI (n=157) Bevacizumab + FOLFIRI (n=149) HR = 0.90 (95% CI: ) p= HR = 0.63 (95% CI: ) p = Months Months Cetuximab + FOLFIRI Bevacizumab + FOLFIRI Numbers at Risk Cetuximab + FOLFIRI Bevacizumab + FOLFIRI Numbers at Risk
22 Distinct Biology of R v. L CRC Analysis of PETACC-3 samples (n=2849) BRAF mut MSI KRAS PIK3CA Mucinous differentiation Right EREG expression 18q loss 20q Gain EGFR gain HER2 gain High mutation Frequency Poor Prognosis Missiaglia, ASCO 2013 Left Sensitive to Cetuximab Good Prognosis
23 LEFTy Organization
24 LEFTy Organization
25 HR for OS According to Primary Tumor Location Loree JM,... Kopetz S; Clin Cancer Res 2018
26 Treatment options based on Location: My Take RAS wt Right-sided Left-sided T + EGFR-i D/T + Bev D + EGFR-i D + Bev if ORR is a primary goal if OS is a primary goal if OS is a primary goal if EGFR-i are not accepted/tolerated D: chemo doublet T: chemo triplet default recommendation default recommendation
27
28 Microsatellite Instability
29 % C h a n g e fro m B a s e lin e S L D % C h a n g e fro m B a s e lin e S L D M M R -p ro fic ie n t C R C M M R -d e fic ie n t C R C Pembrolizumab M M R -p ro fic ie n t C R C M M R -d e fic ie n t C R C MMR-deficient CRC, N=28 MMR-proficient CRC, N=25 Response Rate 57% 0% Disease Control Rate 89% 16% Le DT, et al. NEJM 2015 and ASCO 2016
30 a C h a n g e i n S u m o f T a r g e t L e s i o n s S i z e ( % ) Overman et al. Lancet Oncology 2017 MSI-high CRC: Nivolumab Monotherapy RR 31% SD 39% PD 24% Disease Control 12weeks in 69% On treatment Off treatment CR or PR First occurrence of new lesion O n T r e a t m e n t O f f T r e a t m e n t C o m p l e t e o r P a r t i a l R e s o p o n s e F i r s t O c c u r r e n c e o f N e w L e s i o n C h a n g e T r u n c a t e d t o % W e e k s
31 Investigator-Assessed Best Change in Target Lesion Size (%) Investigator-Assessed Best Change in Target Lesion Size (%) Investigator-Assessed Best Change in Target Lesion Size (%) Reduction in Target Lesions Regardless of PD-L1 Expression, BRAF or Lynch History 100 BRAF Mutation Status Tumor PD-L1 Expression 50 Mutant Wild type + Confirmed CR/PR % < 1% + Confirmed CR/PR Clinical History of Lynch Syndrome Yes No + Confirmed CR/PR Overman et al. Lancet Oncology
32 IMblaze370: randomised, Phase III, multicentre, open-label study in mcrc Loss of clinical benefit Unresectable locally advanced or metastatic CRC Received 2 prior regimens of cytotoxic chemotherapy for metastatic disease ECOG PS 0-1 MSI-H capped at 5% R 2:1:1 N=363 Atezolizumab 840 mg IV q2w + cobimetinib 60 mg oral 21/7 days Atezolizumab 1200 mg IV q3w Regorafenib 160 mg oral 21/7 days Stratification Extended RAS mutation status ( 50% patients in each arm) Time since diagnosis of first metastasis (< 18 months vs 18 months) Primary endpoint OS a Atezo + cobi vs rego Atezo vs rego Data cutoff date: March 9, 2018 INV-assessed key secondary endpoints PFS ORR DOR Atezo, atezolizumab; cobi, cobimetinib; INV, investigator; rego, regorafenib. a Two-sided type I error rate of 0.05 was controlled by hierarchical testing (testing atezo vs rego only if atezo + cobi vs rego was positive). NCT World Congress On Gastrointestinal Cancer, 2018 Bendell J, et al. IMblaze370 32
33 Overall survival Median OS, mo (95% CI) HR vs rego (95% CI) Atezo + cobi (n = 183) 8.9 (7.00, 10.61) 1.00 (0.73, 1.38) Atezo (n = 90) 7.1 (6.05, 10.05) Rego (n = 90) 8.5 (6.41, 10.71) 1.19 (0.83, 1.71) N/A P value a N/A 12-mo OS, % 38.5% 27.2% 36.6% N/A, not applicable. HRs are from stratified log-rank tests. Data cutoff: March 9, a For descriptive purposes only. World Congress On Gastrointestinal Cancer, 2018 Bendell J, et al. IMblaze370 33
34 HER2 Overexpression HER2/neu 3+ (2+)
35 HERACLES Trial Trastuzumab + Lapatinib in HER2+ / KRAS-wt pts refractory to ani-egfr AK 849 patients screened, 46 patients (5.4%) HER2+ (2+/3+); 23 patients evaluable for response ORR 35%, DCR 78% Siena, et al. ASCO 2015
36 Optimal treatment of mcrc in the presence of braf
37 Clinical Efforts in BRAF mut BRAFi+ EGFRi Roche/Genentech BRAFi+ EGFRi + PI3Ki Novartis BRAFi+ EGFRi + chemo US Cooperative Groups BRAFi+ EGFRi + MEKi GSK 37
38 Study Design R E G I S T R A T I O N Local BRAF testing No local BRAF testing BRAF V600E Mutation Central Testing Performed R A N D O M I Z A T I O N ARM 1: Cetuximab + Irinotecan ARM 2: Vemurafenib + Cetuximab + Irinotecan Progression Progression Off Study STEP 3: Crossover to add Vemurafenib Off Study Wild-type (off study) Vemurafenib 960mg PO bid continuous Cetuximab 500mg/m2 IV q2weeks Irinotecan 180mg/m2 IV q2weeks Presented by: Scott Kopetz, MD, PhD
39 Primary Endpoint: Progression-free survival 100% 80% N Events Median 95% Conf Int Cetuximab + Irinotecan ( ) Vemurafenib + Cetuximab ( ) + Irinotecan 60% 40% HR = 0.48 (95% CI ) P= % 0% Months after randomization April data cutoff Presented by: Scott Kopetz, MD, PhD
40 Response Rate 100% Cetuximab + Irinotecan Cetuxim ab + Irinotec an (n=45) a Vemurafe nib + Cetuxima b + Irinotecan (n=43) a P-value c 20% 0% -30% -100% Partial response 4% 16% 100% Vemurafenib + Cetuximab + Irinotecan Stable disease 18% 48% Progression b 56% 12% P= % 0% -30% Disease Control 22% 67% Rate a 93 patients had measurable disease; b Including symptomatic deterioration; c Chi-squared -100% Presented by: Scott Kopetz, MD, PhD April data cutoff
41 BEACON CRC Phase 3 Study Design 1 Safety Lead-in Completed Phase 3 Currently Enrolling ENCO 300 mg QD + BINI 45 mg BID + CETUX 400 mg/m 2 (initial), then 250 mg/m 2 QW R 1:1:1 Triplet therapy ENCO + BINI + CETUX n=205 Doublet Therapy ENCO + CETUX n=205 Control Arm FOLFIRI + CETUX, or IRI + CETUX n=205 Disease progression Disease progression Disease progression Continued follow-up for evaluation of OS N=30 1. Clinicaltrials.gov/ct2/show/NCT ; (February 2018). Van Cutsem et al., ESMO GI 2018
42 Best % Change from Baseline Best Percentage Change in Tumor Measurements from Baseline Cetuximab + Irinotecan from SWOG S P a rtia l R e s p o n s e (n = 1 1 ) C o m p le te R e s p o n s e (n = 3 ) * * * Patients *Patients with lymph node disease with decreases in short axis dimensions consistent with RECIST 1.1 defined Complete Response. One patient had no baseline sum of longest diameters and is not presented. 1. Kopetz S, et al. J Clin Oncol. 2017;35:Abstr 3505, with permission. Van Cutsem et al., ESMO GI 2018
43 Overall survival (%) BEACON SLI: Overall Survival year OS rate: 62% Survival Rate 1 Prior Regimen 2 Prior Regimens 6 mo 88% 85% 12 mo 63% 62% Median OS: Not reached Data fully mature through 12.6 months 10 0 Patients at risk Patients with BRAF V600 mutation (N=29) Censored patients Time (mo) Van Cutsem et al., ESMO GI 2018
44
45 RSK Ras and effector dependencies KRAS subtype lines: depend on the canonical RAS-RAF MAPK pathway upregulate genes involved in the maintenance of the epithelial phenotype RSK subtype lines: depend on the RSK-MTOR/PI3K axis to drive aerobic metabolism to supplement glycolysis express mesenchymal markers ZEB1, TGFB, TWIST KRAS Tina Yuan, Rachel Bagni, Cyril Benes, Arnaud Amzallag, Bob Stephens, Ming Yi, FNLCR Cell Feb 2018
46 KRAS suptype: RAF/MEK/ERK dependencies 1. Inhibition of this signaling with MEK inhibitors such as trametinib, selumetinib alone or in combination 2. Inhibition of ERK with inhibitors such as MK- 8353, BVD Combination of MEK and ERK inhibition to overcome resistance 4. Pan raf inhibitors LY RAF/MEK inhibitor RO Combination of AKT/MEK PI3K/MEK inhibitors 7. Cdk4/6 and MEK inhibitors
47 MLH1 rs Outcome Data from KRAS mut mcrc patients in TRIBE FOLFIRI/bevacizumab arm HR 3.14 (95%CI ) Median OS 25.8 vs 18.4 months
48 CCL2 rs4586 Outcome Data from KRAS mut mcrc patients in TRIBE FOLFIRI/bev Arm HR 0.51 (95%CI ) Median PFS 25.8 vs 18.4 months
49 Current View of mcrc Treatment RAS mutated FOLFOX + Bev FOLFIRI + Bev FOLFOX + cetux BRAF mutated, MSS MSI-High FOLFOXIRI + Bev FOLFOX + Bev Vemurafenib/ Cetuximab/Irinotecan or Clinical Trial PD-1 inhibition Salvage Oral agents: RAS/BRAF wild type Left Sided FOLFOX + Cet/Pan (or Bev) FOLFIRI + Bev (or Cet/Pan) Rego TAS-102 Right Sided FOLFOX + Bev FOLFIRI + Bev Irinotecan + Cetuximab/Pantimumab
50 The one who knows more, may decide better
51
Colorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationColorectal Cancer in the Coming Years: What Can We Expect?
Colorectal Cancer in the Coming Years: What Can We Expect? Clara Montagut, MD, PhD Hospital Universitari del Mar, Barcelona, Spain Memorial Sloan Kettering Cancer Center, New York, United States What Are
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationTherapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer
Therapeutic Options for Patients with BRAF-mutant Metastatic Colorectal Cancer Axel Grothey, M.D., Professor of Oncology, Clinical and Translational Science Division of Medical Oncology Mayo Clinic, Rochester,
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationColon Cancer ASCO Poster Review
Rome, February 11 th 2017 AIOM POST ASCO GI Review Colon Cancer ASCO Poster Review Lisa Salvatore UOC Oncologia Policlinico GB Rossi Azienda Ospedaliero Universitaria Integrata di Verona Me Before Me After
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationRight Drug for the Right Colorectal Patient: Select the Best Initial Therapy and What Comes After 5-FU/OXALI/IRINO?
Right Drug for the Right Colorectal Patient: Select the Best Initial Therapy and What Comes After 5-FU/OXALI/IRINO? Axel Grothey Professor of Oncology Minnesota -> Tennessee The Luxury of So Many Options...
More informationEric Van Cutsem University Hospitals Leuven, Belgium
BEACON CRC Study Safety Lead-in: Assessment of the BRAF Inhibitor Encorafenib + MEK Inhibitor Binimetinib + Anti Epidermal Growth Factor Receptor Antibody Cetuximab for BRAF V600E Metastatic Colorectal
More informationJY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
More informationThe left versus right colon cancer story What is the truth?
The left versus right colon cancer story What is the truth? Prof. V. Heinemann CCC LMU, Klinikum Grosshadern Ludwig-Maximilian-University of Munich, Germany Three stages of truth (Schopenhauer) Ridicule
More informationRandomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406) ASCO Annual Meeting 2017 Randomized trial of irinotecan and cetuximab with
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationESMO GI / BEACON CRC SAFETY LEAD-IN ENCORE PRESENTATION June 23, 2018
ESMO GI / BEACON CRC SAFETY LEAD-IN ENCORE PRESENTATION June 23, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationPresentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
More informationJY Douillard MD, PhD Professor of Medical Oncology
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Vienna 26-27 Program October 2015 Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer
More informationAIOM GIOVANI Perugia, Luglio 2017
AIOM GIOVANI 2017 Perugia, 07-08 Luglio 2017 Scelta delle linee successive nel paziente RAS e BRAF wild-type con particolare accento su nuovi bersagli terapeutici Francesca Battaglin U.O.C. Oncologia Medica
More informationNovel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer. Objectives
Novel Molecularly Targeted Therapies and Biomarkers in Advanced Colorectal Cancer Michael S. Lee, MD Assistant Professor of Medicine University of North Carolina Objectives Discuss important clinicopathologic
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationCURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES
CURRENT STANDARD OF CARE OF COLORECTAL CANCER: THE EVOLUTION OF ESMO CLINICAL PRACTICE GUIDELINES Fortunato Ciardiello ESMO Past-President 2018-2019 Dipartimento di Medicina di Precisione Università degli
More informationReview of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux
Review of the ESMO consensus conference on metastatic CRC Basis strategies ad groups (RAS, BRAF, etc) Michel Ducreux 2 ESMO consensus on mcrc 2016 Chairs: Co-Chairs of working groups E Van Cutsem A Sobrero
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationColorectal Cancer: Novel Insights
Colorectal Cancer: Novel Insights Richard Kim M.D. Associate Professor Service Chief of Medical Oncology Department of Gastrointestinal Oncology Moffitt Cancer Center Tampa, FL Richard Kim, MD Colorectal
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationArray BioPharma Jefferies 2016 Global Healthcare Conference. June 9, 2016
Array BioPharma Jefferies 216 Global Healthcare Conference June 9, 216 Safe Harbor Statement 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationDaniele Santini University Campus Bio-Medico Rome, Italy
Daniele Santini University Campus Bio-Medico Rome, Italy Anti EGFR therapy and colorectal cancer Cetuximab or Panitumumab Adapted from Ciardiello F. and Tortora G. NEJM 2008;358:1160-74 Who will benefit
More informationColon cancer: ASCO poster review. Alfonso De Stefano MD, PhD SC Oncologia Clinica Sperimentale Addome
Colon cancer: ASCO poster review Alfonso De Stefano MD, PhD SC Oncologia Clinica Sperimentale Addome a.destefano@istitutotumori.na.it 255 poster examined: my selection Clinical Practice Translational &
More informationNOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO
Congresso AIOM Giovani Perugia, 9 luglio 2016 NOVITA IN TEMA DI TERAPIA DEL CARCINOMA DEL COLON-RETTO Carlotta Antoniotti Polo Oncologico Azienda Ospedaliero-Universitaria Pisana Università di Pisa What
More informationDoes it matter which chemotherapy regimen you partner with the biologic agents?
Does it matter which chemotherapy regimen you partner with the biologic agents? Yes, it does matter! Axel Grothey Disclosures Research Funding to MAYO Clinic Genentech Bayer Eisai Pfizer Imclone Potential
More informationDr. Iain Tan. Senior Consultant GI Medical Oncologist National Cancer Centre Singapore
ESMO-ASIA 2017 Preceptorship (GI cancers) Session: Metastatic colorectal cancer, liver limited metastases Topic: Unresectable or borderline resectable : chemotherapy +/- targeted agents Dr. Iain Tan Senior
More informationKeynote Presentation I New Era of CRC Management: Impact of Tumor Sidedness and Molecular Subtypes of CRC
Keynote Presentation I New Era of CRC Management: Impact of Tumor Sidedness and Molecular Subtypes of CRC Scott Kopetz, MD, PhD, FACP University of Texas MD Anderson Cancer Center Houston, Texas, United
More informationFirst line treatment in metastatic colorectal cancer
First line treatment in metastatic colorectal cancer Claus-Henning Köhne University Clinic Onkology and Haematology North West German Cancer Center (NWTZ) A non authorised version of ESMO guidelines was
More informationMANAGEMENT OF ADVANCED COLORECTAL CANCER
MANAGEMENT OF ADVANCED COLORECTAL CANCER Alberto Sobrero IRCCS San Martino IST Genoa Italy Disclosures : Pfizer, Roche, Merck, Amgen, Celgene, Bayer, Sanofi, Nordic, Takeda,BMS, Syrtex, Servier outline
More informationReview of the ESMO consensus conference on metastatic colorectal cancer Basic strategies and groups. Chemotherapy and targeted agents in 1st line
ESMO Preceptorship Programme Colorectal Cancer Valencia, 18th May 2018 Review of the ESMO consensus conference on metastatic colorectal cancer Basic strategies and groups Chemotherapy and targeted agents
More informationOPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER
OPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER E-Learning Module Stavros Gkolfinopoulos 1, Demetris Papamichael 1, George Pentheroudakis 2 1. Cyprus Oncology Centre, Nicosia, Cyprus 2.
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationCarcinoma colorettale: personalizzazione del trattamento
33 Incontro Oncologico del Triveneto Padova, Aprile 2017 Carcinoma colorettale: personalizzazione del trattamento Fotios Loupakis, MD PhD U.O.C. Oncologia Medica 1 Dipartimento di Oncologia Clinica e Sperimentale
More informationMÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO. Dra. Ruth Vera Complejo Hospitalario de Navarra
MÁS ALLA DE LA PRIMERA LÍNEA: SECUENCIA DE TRATAMIENTO Dra. Ruth Vera Complejo Hospitalario de Navarra GOALS Prolongation of survival Cure Improving tumour-related symptoms Stopping tumour progression
More informationCOMETS: COlorectal MEtastatic Two Sequences
COMETS: COlorectal MEtastatic Two Sequences A Phase III Multicenter Trial Comparing Two Different Sequences of Second/Third Line Therapy (Irinotecan/Cetuximab Followed By FOLFOX-4 vs. FOLFOX-4 Followed
More informationManaging mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression
Managing mcrc Across Disease Continuum: Front-Line Therapy and Treatment Beyond Progression Guillermo Méndez, MD Sección Oncología Hospital de Gastroenterología Bonorino Udaondo Carlos B. Udaondo y Fundación
More informationANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria
IS IT TIME TO RE-CHALLENGE ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria Dr. Andrea Sartore-Bianchi, Oncologia Clinica Molecolare, Niguarda Cancer Center, Milano,
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationAxel Grothey West Cancer Center University of Tennessee, Germantown, TN, USA
Updated Results of the BEACON CRC Safety Lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mcrc) Axel Grothey West Cancer Center University
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationManagement of Patients with Colorectal Cancer
Management of Patients with Colorectal Cancer Elsevier Office of Continuing Medical Education Independent Conference Highlights of the ASCO-GI 2018 Symposium Disclaimer The views expressed in the following
More informationXXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione?
XXV Corso Nazionale TSLB: evoluzione o ri(e)voluzione? Marcatori predittivi di efficacia nel carcinoma del colon: DESTRO verso SINISTRO conta? Dott. Matteo Clavarezza S.C. Oncologia Medica RAS metastatic
More informationKolorektalni karcinom- novosti u liječenju. PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić
Kolorektalni karcinom- novosti u liječenju PANEL: Maja Banjin, Janja Ocvirk, Borislav Belev, Ivan Nikolić, Anes Pašić Kolorektalni karcinomnovosti u liječenju PANEL : Maja Banjin, Janja Ocvirk, Borislav
More informationArray BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018
Array BioPharma Second Quarter of F2018 Update FEBRUARY 6, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationColon Cancer Molecular Target Agents
Colon Cancer Molecular Target Agents Ci Caio Max SR S. Rocha Lima, M.D. MD Professor of Medicine CDi CoDiretor Cl Colorectal tlheptobiliary, Pancreatic SDG, and Phase I Unit University of Miami & Silvester
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationValidated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD
Validated and promising predictive factors in mcrc: Recent updates on RAS testing Fotios Loupakis, MD PhD U.O. Oncologia 2 Universitaria Azienda Ospedaliero-Universitaria Pisana Pisa, Italy Learning Objectives
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationFighting a Smarter War On Colon Cancer:
Fighting a Smarter War On Colon Cancer: Value as a new endpoint? John L. Marshall, MD Tel: (202) 444-0275 Fax: (202) 444-1229 http://lombardi.georgetown.edu/gi Stakeholder Motivation Stakeholders FDA CMS/Payers
More informationMSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany
MSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory boards for AMGEN, ROCHE I Speaker
More informationHeavilyTreated mcrc..whats next?
ESMO Preceptorship Programme Gastrointestinal Cancer 20-22 October 2016,Singapore Dr Surendra Pal Chaudhary Dept of Medical Oncology Dr BR Ambedkar Instituite Rotary Cancer Hospital All India Institute
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationArray BioPharma Third Quarter of F2018 Update MAY 9, 2018
Array BioPharma Third Quarter of F2018 Update MAY 9, 2018 SAFE HARBOR STATEMENT Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions of the
More informationGI SLIDE DECK 2016 Selected abstracts on Colorectal Cancer from:
GI SLIDE DECK 216 Selected abstracts on Colorectal Cancer from: ESMO 216 Congress 7 11 October 216 Copenhagen, Denmark Supported by Eli Lilly and Company. Eli Lilly and Company has not influenced the content
More informationMedical Therapy of Colorectal Cancer in the Biomarker Era
Medical Therapy of Colorectal Cancer in the Biomarker Era Axel Grothey Professor of Oncology Mayo Clinic College of Medicine Rochester, Minnesota Disclosures Consulting activities (honoraria went to the
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationColorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC
Colorectal Cancer: Lumping or Splitting? Jimmy J. Hwang, MD FACP Levine Cancer Institute Carolinas HealthCare System Charlotte, NC 2 Epidemiology Colorectal Cancer is the 2 nd Leading Cause of Cancer-related
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationNSCLC 2 nd and further line therapies. Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute
NSCLC 2 nd and further line therapies Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute e.smit@nki.nl ESMO Guidelines 2016: Treatment of Stage IV nonsquamous NSCLC at progression
More informationAshita Waterston Beatson West of Scotland Cancer Centre
Ashita Waterston Beatson West of Scotland Cancer Centre Aim of treatment Scheduling and choice of treatments are dictated by aim: Down staging for resectability: upfront intensive Prolong survival: combination
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Royal Marsden Hospital ESMO Colorectal Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role Servier, Celgene, BMS, Five
More informationHistology independent indications in oncology. The BRAF Story. Yibing Yan PhD Roche / Genentech
Histology independent indications in oncology The BRAF Story Yibing Yan PhD Roche / Genentech 1 Introduction the discovery Case study in BRAF mutant melanoma heterogeneity within the tumour variability
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationAbetter understanding of the tumor biology of colorectal cancer has led to. Beyond the second line
Beyond the second line of the care continuum in metastatic colorectal cancer In first-line treatment, a deep response on the tumor load is the primary aim to improve patient prognosis; however, in later
More informationRecent Advances in Gastrointestinal Cancers
Recent Advances in Gastrointestinal Cancers Ursina R. Teitelbaum, MD Section of Hematology/Oncology Abramson Cancer Center PENN 2016 Updates in Oncology June 23, 2016 none Disclosures ASCO 2016 Highlights:
More informationDevelopment of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical modulation, Oral fluoropyrimidines, Developmentof combination chemotherapy
ESMO Preceptorship Colorectal Cancer Colorectal ESMO Cancer Preceptorship Valencia May Program 20-21st 2016 Prague May 22-23rd 2014 Development of Conventional Chemotherapy in mcrc BSC vs. Chemo, Biochemical
More informationToxicity by Age Group. Old Factor 1: Age. Disclosures. Predicting survival in metastatic colorectal cancer. Personalized Medicine - Decision Tools -
Disclosures Predicting survival in metastatic colorectal cancer Daniel Sargent, PhD Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis Genomic Health Personalized Medicine -
More informationTHE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER
THE ROLE OF PREDICTIVE AND PROGNOSTIC MARKERS IN COLORECTAL CANCER Cathy Eng, M.D., F.A.C.P. Associate Professor Associate Medical Director, Colorectal Center Dept of GI Medical Oncology November 5, 2010
More informationNivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142
Nivolumab in Patients With DNA Mismatch Repair Deficient/Microsatellite Instability High Metastatic Colorectal Cancer: Update From CheckMate 142 Abstract #519 Overman MJ, Lonardi S, Leone F, McDermott
More informationUnmet Need Mucosal and Uveal Melanoma
Unmet Need Mucosal and Uveal Melanoma Matteo Carlino Crown Princess Mary Cancer Centre Westmead and Blacktown Hospitals Melanoma Institute Australia The University of Sydney. Cutaneous Overall Survival
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationNew Developments in the Treatment of Colorectal Cancer. Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre
New Developments in the Treatment of Colorectal Cancer Jonathan Loree, MD, MS, FRCPC Department of Medical Oncology BC Cancer Vancouver Centre Personalized Medicine Currently already part of oncology:
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationColon Cancer Update Christie J. Hilton, DO
POMA Winter Conference Christie Hilton DO Medical Oncology January 2018 None Colon Cancer Numbers Screening (brief update) Practice changing updates in colon cancer MSI Testing Immunotherapy in Colon Cancer
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationCTC in clinical studies: Latest reports on GI cancers
CTC in clinical studies: Latest reports on GI cancers François-Clément Bidard, MD PhD GI cancers are characterized by Multimodal treatment strategies Treatments are adapted to tumor burden & prognosis
More informationTreatment of Advanced Colorectal Cancer
Treatment of Advanced Colorectal Cancer Alexis D. Leal, M.D. Assistant Professor, GI Medical Oncology University of Colorado Cancer Center Disclosures None Objectives Review the basics of advanced colorectal
More informationPerioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy?
Perioperative chemotherapy for colorectal cancer livermetastases: what is the optimal strategy? Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be A classical case
More informationRAS and BRAF in metastatic colorectal cancer management
Review Article RAS and BRAF in metastatic colorectal cancer management Jun Gong 1, May Cho 1, Marwan Fakih 2 1 Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA; 2 Medical
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationDOES LOCATION MATTER IN COLORECTAL CANCER: LEFT VS RIGHT?
DOES LOCATION MATTER IN COLORECTAL CANCER: LEFT VS RIGHT? By: Dr. Dominik Modest, Medical Department III, Hospital of the University of Munich, Germany Dr. Andrea Sartore-Bianchi, Niguarda Cancer Center,
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationBasket Trials: Features, Examples, and Challenges
: Features, s, and Challenges Lindsay A. Renfro, Ph.D. Associate Professor of Research Division of Biostatistics University of Southern California ASA Biopharm / Regulatory / Industry Statistics Workshop
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationHow to treat a patient with metastatic CRC? Towards personalized treatment strategies
How to treat a patient with metastatic CRC? Towards personalized treatment strategies Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium Eric.VanCutsem@uzleuven.be Progress in the treatment
More informationTHE BEST OF ESMO 2016
THE BEST OF ESMO 2016 Colorectal cancer Pr Julien TAIEB, Sorbonne Paris Cité and Paris Descartes University Georges Pompidou European Hospital Paris, FRANCE esmo.org DISCLOSURES JT has received research
More information